Fol. Biol. 2017, 63, 20-26
https://doi.org/10.14712/fb2017063010020
Gelatinases A and B and Antioxidant Enzyme Activity in the Early Phase of Acute Myocardial Infarction
References
1. 2006) Matrix metalloproteinases and cardiovascular disease. Eur. Heart J. 27, 121-122.
< , S. (https://doi.org/10.1093/eurheartj/ehi639>
2. 1952) A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J. Biol. Chem. 195, 133-140.
< , R. F., Sizer, I. W. (https://doi.org/10.1016/S0021-9258(19)50881-X>
3. 1987) Allopurinol in prevention of reperfusion injury of hypoxically stored rat hearts. J. Heart Transplant. 6, 137-140.
, J., LoBalsamo, L., Lajos, P., Feldman, M. J., Mookerjee, B. (
4. 2010) Matrix metalloproteinase-9 activity is associated to oxidative stress in patients with acute coronary syndrome. Int. J. Cardiol. 143, 98-100.
< , A., Alcaíno, H., Castro, P. F., Pérez, O., Corbalán, R., Troncoso, R., Chiong, M., Mellado, R., Moraga, F., Zanolli, D., Winter, J. L., Zamorano, J. J., Díaz-Araya, G., Lavandero, S. (https://doi.org/10.1016/j.ijcard.2008.11.188>
5. 1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
< , M. M. (https://doi.org/10.1016/0003-2697(76)90527-3>
6. 2014) Over-expression of catalase in myeloid cells confers acute protection following myocardial infarction. Int. J. Mol. Sci. 15, 9036-9050.
< , E. B., Somasuntharam, I., Brown, M. E., Che, P. L., Pendergrass, K. D., Chiang, B., Taylor, W. R., Davis, M. E. (https://doi.org/10.3390/ijms15059036>
7. 1985) Glutathione reductase. Methods Enzymol. 113, 484-490.
< , I., Mannervik, B. (https://doi.org/10.1016/S0076-6879(85)13062-4>
8. 2010) Biomarkers in acute myocardial infarction. BMC Med. 8, 34-45.
< , D., Ng, L. L. (https://doi.org/10.1186/1741-7015-8-34>
9. 2009) Oxidative stress as a mediator of cardiovascular disease. Oxid. Med. Cell. Longev. 2, 259-269.
< , M. M., Kong, Y. X., Matata, B. M. (https://doi.org/10.4161/oxim.2.5.9441>
10. 1984) Oxygen radicals in biological systems. Methods Enzymol. 37, 93-104.
< , L., Otting, F. (https://doi.org/10.1016/S0076-6879(84)05013-8>
11. 2012) Free radicals and antioxidants: updating a personal view. Nutr. Rev. 70, 257-265.
< , B. (https://doi.org/10.1111/j.1753-4887.2012.00476.x>
12. 2005) NO/redox disequilibrium in the failing heart and cardiovascular system. J. Clin. Invest. 115, 509-517.
< , J. M., Stamler, J. S. (https://doi.org/10.1172/JCI200524459>
13. 2004) Upregulation of vascular extracellular superoxide dismutase in patients with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 24, 106-111.
< , M., Tsutsui, M., Tasaki, H., Morishita, T., Suda, O., Nakata, S., Nihei, S., Miyamoto, M., Kouzuma, R., Okazaki, M., Yanagihara, N., Adachi, T., Nakashima, Y. (https://doi.org/10.1161/01.ATV.0000104240.56460.AB>
14. 2003) Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur. Heart J. 24, 2180-2185.
< , K., Matsunaga, T., Abe, N., Hanada, H., Ishizaka, H., Ono, H., Saitoh, M., Fukui, K., Fukuda, I., Osanai, T., Okumura, K. (https://doi.org/10.1016/j.ehj.2003.09.022>
15. 2014) The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke. Int. J. Neurosci. 124, 707-716.
< , J., Kurzepa, J., Golab, P., Czerska, S., Bielewicz, J. (https://doi.org/10.3109/00207454.2013.872102>
16. 2004) Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast sera. Br. J. Cancer 90, 1414-1421.
< , G., Pucci-Minafra, I., Marrazzo, A., Taormina, P., Minafra, S. (https://doi.org/10.1038/sj.bjc.6601725>
17. 2006) Matrix metalloproteinases in cardiovascular disease. Can. J. Cardiol. 22, 25B-30B.
< , P., Sun, M., Sader, S. (https://doi.org/10.1016/S0828-282X(06)70983-7>
18. 2009) NO generation from inorganic nitrate and nitrite: role in physiology, nutrition and therapeutics. Arch. Pharm. Res. 32, 1119-1126.
< , J. O., Weitzberg, E. (https://doi.org/10.1007/s12272-009-1803-z>
19. 1998) Semiautomated measurement of nitrate in biological fluids. Clin. Chem. 44, 679-681.
< , J. A., Garcia-Benayas, C., Arenas, J. (https://doi.org/10.1093/clinchem/44.3.679>
20. 2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 94, 1543-1553.
< , M., Lee, P., Khaper, N., Liu, P. (https://doi.org/10.1161/01.RES.0000130526.20854.fa>
21. 2011) Temporal effects of catalase overexpression on healing after myocardial infarction. Circ. Heart Fail. 4, 98-106.
< , K. D., Varghese, S. T., Maiellaro-Rafferty, K., Brown, M. E., Taylor, W. R., Davis, M. E. (https://doi.org/10.1161/CIRCHEARTFAILURE.110.957712>
22. 2011) Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species. World J. Cardiol. 3, 186-200.
< , M. G., Pagliaro, P., Penna, C. (https://doi.org/10.4330/wjc.v3.i6.186>
23. 2007) Matrix metalloproteinases and myocardial infarction. Can. J. Cardiol. 23, 727-733.
< , W., Phrommintikul, A., Chattipakorn, N. (https://doi.org/10.1016/S0828-282X(07)70818-8>
24. 2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587-596.
< , H. J., Parks, W. C. (https://doi.org/10.1016/j.matbio.2007.07.001>
25. 1978) Determination of superoxide dismutase in erythrocytes using the method of adrenaline autooxidation. Anal. Biochem. 90, 81-89.
< , M., Zigman, S. (https://doi.org/10.1016/0003-2697(78)90010-6>
26. 2012) Early loss of cardiac function in acute myocardial infarction is associated with redox imbalance. Exp. Clin. Cardiol. 17, 263-267.
, A. M., da Rosa Araujo, A. S., Llesuy, S., Khaper, N., Rohde, L. E., Clausell, N., Bello-Klein, A. (
27. 2012) Third universal definition of myocardial infarction. J. Am. Coll. Cardiol. 60, 1581-1598.
< , K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D.; Joint ESC/ACCF/AHA/ WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons, Thygesen, K., Alpert, J. S., White, H. D.; Biomarker Subcommittee, Jaffe, A. S., Katus, H. A., Apple, F. S., Lindahl, B., Morrow, D. A.; ECG Subcommittee, Chaitman, B. R., Clemmensen, P. M., Johanson, P., Hod, H.; Imaging Subcommittee, Underwood, R., Bax, J. J., Bonow, J. J., Pinto, F., Gibbons, R. J.; Classification Subcommittee, Fox, K. A., Atar, D., Newby, L. K., Galvani, M., Hamm, C. W.; Intervention Subcommittee, Uretsky, B. F., Steg, P. G., Wijns, W., Bassand, J. P., Menasche, P., Ravkilde, J.; Trials & Registries Subcommittee, Ohman, E. M., Antman, E. M., Wallentin, L. C., Armstrong, P. W., Simoons, M. L.; Trials & Registries Subcommittee, Januzzi, J. L., Nieminen, M. S., Gheorghiade, M., Filippatos, G.; Trials & Registries Subcommittee, Luepker, R. V., Fortmann, S. P., Rosamond, W. D., Levy, D., Wood, D.; Trials & Registries Subcommittee, Smith, S. C., Hu, D., Lopez-Sendon, J. L., Robertson, R. M., Weaver, D., Tendera, M., Bove, A. A., Parkhomenko, A. N., Vasilieva, E. J., Mendis, S.; ESC Committee for Practice Guidelines (CPG), Bax, J. J., Baumgartner, H., Ceconi, C., Dean, V., Deaton, C., Fagard, R., Funck-Brentano, C., Hasdai, D., Hoes, A., Kirchhof, P., Knuuti, J., Kolh, P., McDonagh, T., Moulin, C., Popescu, B. A., Reiner, Z., Sechtem, U., Sirnes, P. A., Tendera, M., Torbicki, A., Vahanian, A., Windecker, S.; Document Reviewers, Morais, J., Aguiar, C., Almahmeed, W., Arnar, D. O., Barili, F., Bloch, K. D., Bolger, A. F., Botker, H. E., Bozkurt, B., Bugiardini, R., Cannon, C., de Lemos, J., Eberli, F. R., Escobar, E., Hlatky, M., James, S., Kern, K. B., Moliterno, D. J., Mueller, C., Neskovic, A. N., Pieske, B. M., Schulman, S. P., Storey, R. F., Taubert, K. A., Vranckx, P., Wagner, D. R. (https://doi.org/10.1016/j.jacc.2012.08.001>
28. 2009) Oral administration of L-arginine in patients with angina or following myocardial infarction may be protective by increasing plasma superoxide dismutase and total thiols with reduction in serum cholesterol and xanthine oxidase. Oxid. Med. Cell. Longev. 2, 231-237.
< , P., Chandra, M., Misra, M. K. (https://doi.org/10.4161/oxim.2.4.9233>
29. 1991) Concentration of Mn-superoxide dismutase in serum in acute myocardial infarction. Clin. Chem. 37, 458-461.
< , A., Kato, K., Tsuboi, H., Sone, T., Sassa, H., Abe, T. (https://doi.org/10.1093/clinchem/37.3.458>
30. 1998a) Overexpression of human copper, zinc-superoxide dismutase (SOD1) prevents post ischemic injury. Proc. Natl. Acad. Sci. USA 95, 4556-4560.
< , P., Chen, H., Qin, H., Sankarapandi, S., Becher, M. W., Wong, P. C., Zweier, J. L. (https://doi.org/10.1073/pnas.95.8.4556>
31. 1998b) Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 18, 1915-1921.
< , X. L., Adachi, T., Sim, A. S., Wilcken, D. L. (https://doi.org/10.1161/01.ATV.18.12.1915>
32. 1981) Glutathione peroxidase. Methods Enzymol. 77, 325-333.
< , A. (https://doi.org/10.1016/S0076-6879(81)77046-0>
33. 1959) Further studies with xanthine oxidase inhibitors. J. Biol. Chem. 234, 1897-1900.
< , W. W., Richert, D. A., Higgins, E. S. (https://doi.org/10.1016/S0021-9258(18)69945-4>
34. 2013) Matrix metalloproteinases: drug targets for myocardial infarction. Curr. Drug Targets 14, 276-286.
, A., Li, Y., Chilton, R., Lindsay, M. (